The activity of cabozantinib and the combination of cabozantinib and erlotinib in the changing landscape of therapy for patients with EGFR mutant NSCLC suggests that further evaluation in selected population may lead to benefits for patients. Here, EGFR is linked to non-small cell lung carcinoma.